In a recent study, women with symptomatic uterine fibroids saw reduced symptom burden and improved quality of life after 24 weeks of treatment through relugolix combination therapy.
Women with symptomatic uterine fibroids achieved a greater improvement in quality of life with myomectomy than with uterine artery embolization (UAE), according to a randomized study published in the journal Health Technology Assessment.
A study published in Women’s Health Reports offers deeper knowledge of women’s lived experience with fibroids in their own words, and confirms the burden of the disease.
A prospective study published in the International Scientific Research Journal has found that colposcopy was able to detect exoservicitis in about one-third of women with uterine fibroids.
The US Food and Drug Administration has accepted to review the supplemental New Drug Application for Myfembree for the potential treatment of heavy menstrual bleeding associated with uterine fibroids for up to 2 years.